Literature DB >> 1706085

Management of labyrinthine fistulas caused by cholesteatoma.

S C Parisier1, D R Edelstein, J C Han, M H Weiss.   

Abstract

The surgical management of labyrinthine fistulas caused by cholesteatoma remains controversial. Forty cases (41 ears) of labyrinthine fistulas were reviewed. This represented 10% of our total series of cholesteatomas in adults and children (426 ears). Clinical presentation, extent of disease, results of fistula testing and audiometric studies, and radiographic findings were analyzed. A canal wall-down procedure was performed in all but one patient. Generally an attempt was made to completely remove the cholesteatoma, to graft the fistulous area, and to reconstruct the middle ear mechanism in one stage. The matrix was preserved in patients with large fistulas where the involved ear was the only hearing one, when the matrix was adherent to the underlying optic duct, and in selected elderly persons. Long-term followup did not reveal a significant difference in hearing, degree of vertigo, or incidence of recidivism when those patients in whom the matrix was removed were compared with those in whom the matrix was preserved. The importance of recognizing the presence of a labyrinthine fistula preoperatively is stressed, along with the need to be prepared for an unexpected fistula. Operative management is described.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706085     DOI: 10.1177/019459989110400120

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  9 in total

1.  Computed tomography in chronic suppurative otitis media: value in surgical planning.

Authors:  Garg Payal; Kulshreshtha Pranjal; Motwani Gul; M K Mittal; A K Rai
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-11-05

2.  Positive perilymph fistula test with semicircular canal dehiscence from cholesteatoma.

Authors:  Ming-Chih Hsieh; Chen Chi Wu; Shih-Hao Wang
Journal:  CMAJ       Date:  2019-01-28       Impact factor: 8.262

3.  Lateral semicircular canal fistula in cholesteatoma: diagnosis and management.

Authors:  Anais Meyer; Pierre Bouchetemblé; Bertrand Costentin; Danièle Dehesdin; Yannick Lerosey; Jean-Paul Marie
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-09-08       Impact factor: 2.503

4.  Prognostic indicators of hearing after complete resection of cholesteatoma causing a labyrinthine fistula.

Authors:  Marie-France Stephenson; Issam Saliba
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-09       Impact factor: 2.503

5.  Facial canal dehiscence, dural exposure, and labyrinthine fistula in middle ear cholesteatoma and mastoiditis.

Authors:  Ning-Chia Chang; Shu-Yu Tai; Kuan-Hui Li; Hua-Ling Yang; Kuen-Yao Ho; Chen-Yu Chien
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-04       Impact factor: 3.236

6.  Post-operative hearing among patients with labyrinthine fistula as a complication of cholesteatoma using "under water technique".

Authors:  K Thangavelu; R Weiß; J Mueller-Mazzotta; M Schulze; B A Stuck; K Reimann
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-09-20       Impact factor: 3.236

7.  Clinical Characteristics of Patients with Cochlear Fistulas Caused by Chronic Otitis Media with Cholesteatoma.

Authors:  Woongsang Sunwoo; Sang-Youp Lee; Jeon Seong; Young Eun Han; Min-Hyun Park
Journal:  J Int Adv Otol       Date:  2020-04       Impact factor: 1.017

8.  Labyrinthine Fistulae in Squamosal Type of Chronic Otitis Media: Therapeutic Outcome.

Authors:  Priyanka Misale; Anjali Lepcha; Ramanathan Chandrasekharan; Manusrut Manusrut
Journal:  Iran J Otorhinolaryngol       Date:  2019-05

9.  Correlation between peri-operative complication in middle ear cholesteatoma surgery using STAMCO, ChOLE, and SAMEO-ATO classifications.

Authors:  Tommaso Cacco; Stefano Africano; Gilda Gaglio; Luca Carmisciano; Enrico Piccirillo; Eolo Castello; Giorgio Peretti
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-22       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.